Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice

被引:4
作者
Wirrell, Elaine C. [1 ]
Lagae, Lieven [2 ]
Scheffer, Ingrid E. [3 ,4 ]
Cross, J. Helen [5 ,6 ]
Specchio, Nicola [7 ]
Strzelczyk, Adam [8 ,9 ]
机构
[1] Mayo Clin, Dept Neurol, Div Child & Adolescent Neurol & Epilepsy, 200 1st St SW, Rochester, MN 55905 USA
[2] Univ Leuven, Dept Pediat Neurol, European Reference Network EpiCARE, Leuven, Belgium
[3] Univ Melbourne, Austin Hosp, Florey & Murdoch Childrens Res Inst, Melbourne, Vic, Australia
[4] Univ Melbourne, Royal Childrens Hosp, Florey & Murdoch Childrens Res Inst, Melbourne, Vic, Australia
[5] UCL NIHR BRC Great Ormond St Inst Child Hlth, Dev Neurosci Res & Teaching Dept, London, England
[6] Great Ormond St Hosp Sick Children, Dept Neurol, London, England
[7] SIPSIC, Rome, Italy
[8] Univ Hosp Frankfurt, Goethe Univ Frankfurt, Epilepsy Ctr Frankfurt Rhine Main, Frankfurt, Germany
[9] Univ Hosp Frankfurt, Dept Neurol, Frankfurt, Germany
关键词
antiseizure medications; Dravet syndrome; fenfluramine; Lennox-Gastaut syndrome; polytherapy; SEVERE MYOCLONIC EPILEPSY; ANTI-SEIZURE MEDICATIONS; DRUG-INTERACTIONS; TERM EFFICACY; RISK-FACTORS; INFANCY; METAANALYSIS; POPULATION; DIAGNOSIS;
D O I
10.1002/epi4.12998
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Fenfluramine (FFA), an antiseizure medication (ASM) with serotonergic and sigma-1 receptor activity, is used to manage patients with developmental and epileptic encephalopathies (DEEs). It is approved in the US for treating seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients >= 2 years old and as add-on therapy for seizures associated with DS and LGS in the EU, UK, and Japan in similarly aged patients. Consensus guidelines for treatment of DS have recommended FFA to be an early-line ASM, and it has also shown efficacy in managing seizures associated with LGS. DS and LGS are DEEs associated with a range of seizure types, developmental impairments, and multiple comorbidities. Here we provide case vignettes describing 4 patients (3 DS and 1 LGS) aged 4-29 years old in whom up to 14 ASMs had previously failed, to illustrate real-world practice issues encountered by neurologists. This review provides guidance on the use of FFA in the context of ASM polytherapy and drug-drug interactions (DDIs), behavioral issues, dose titration, and adverse events. Along with data from the clinical trial program, these case vignettes emphasize the low risk of DDIs, a generally well-tolerated safety profile, and other seizure and nonseizure benefits (eg, improved cognition and sleep) associated with the use of FFA in DS or LGS.Plain Language SummaryFenfluramine is used to treat seizures in individuals with Dravet syndrome and Lennox-Gastaut syndrome, but there are a range of issues that clinicians may face when treating patients. This review highlights four patients from the authors' everyday clinical work and offers guidance and practical considerations by neurologists with expertise in managing these complex conditions related to drug interactions, dosing, and side effects associated with fenfluramine. This is a graphical representation of the abstract and article highlights. image
引用
收藏
页码:1643 / 1657
页数:15
相关论文
共 50 条
  • [21] Few individuals with Lennox-Gastaut syndrome have autism spectrum disorder: a comparison with Dravet syndrome
    He, Na
    Li, Bing-Mei
    Li, Zhao-Xia
    Wang, Jie
    Liu, Xiao-Rong
    Meng, Heng
    Tang, Bin
    Bian, Wen-Jun
    Shi, Yi-Wu
    Liao, Wei-Ping
    JOURNAL OF NEURODEVELOPMENTAL DISORDERS, 2018, 10
  • [22] SCN1A mutation screening in adult patients with Lennox-Gastaut syndrome features
    Selmer, Kaja Kristine
    Lund, Caroline
    Brandal, Kristin
    Undlien, Dag Erik
    Brodtkorb, Eylert
    EPILEPSY & BEHAVIOR, 2009, 16 (03) : 555 - 557
  • [23] Comorbidities in Dravet Syndrome and Lennox–Gastaut Syndrome
    Francesca Marchese
    Simona Cappelletti
    Melissa Filippini
    Cristiana Alessia Guido
    Claudia Passamonti
    Barbara Pucci
    Michela Sole
    Pasquale Striano
    SN Comprehensive Clinical Medicine, 2021, 3 (10) : 2167 - 2179
  • [24] An Italian consensus on the management of Lennox-Gastaut syndrome
    Riva, Antonella
    Coppola, Antonietta
    Di Bonaventura, Carlo
    Elia, Maurizio
    Ferlazzo, Edoardo
    Gobbi, Giuseppe
    Marini, Carla
    Meletti, Stefano
    Romeo, Antonino
    Santoro, Katia
    Verrotti, Alberto
    Capovilla, Giuseppe
    Striano, Pasquale
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2022, 101 : 134 - 140
  • [25] LENNOX-GASTAUT SYNDROME IN THE ELDERLY
    BENBADIS, SR
    DINNER, DS
    CLINICAL ELECTROENCEPHALOGRAPHY, 1994, 25 (04): : 142 - 147
  • [26] Optimizing clobazam treatment in patients with Lennox-Gastaut syndrome
    Isojarvi, Jouko
    Gidal, Barry E.
    Chung, Steve
    Wechsler, Robert T.
    EPILEPSY & BEHAVIOR, 2018, 78 : 149 - 154
  • [27] Clobazam for patients with Lennox-Gastaut syndrome and epilepsy
    Seif-Eddeine, Hussam
    Ng, Yu-Tze
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2012, 12 (04) : 385 - 393
  • [28] The nosology of Lennox-Gastaut syndrome
    Hirt, HR
    NERVENARZT, 1996, 67 (02): : 109 - 122
  • [29] The pharmacological management of Lennox-Gastaut syndrome and critical literature review
    Verrotti, Alberto
    Striano, Pasquale
    Iapadre, Giulia
    Zagaroli, Luca
    Bonanni, Paolo
    Coppola, Giangennaro
    Elia, Maurizio
    Mecarelli, Oriano
    Franzoni, Emilio
    De Liso, Paola
    Vigevano, Federico
    Curatolo, Paolo
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2018, 63 : 17 - 25
  • [30] Development and refinement of the Clinical Global Impression of Improvement for Non-seizure Symptoms measure in Dravet syndrome and Lennox-Gastaut syndrome
    Andrews, J. Scott
    Shah, Drishti
    Nacson, Alise
    Symonds, Tara
    Hughes, Sophie
    Asgharnejad, Mahnaz
    Benitez, Arturo
    Sams, Lara
    JOURNAL OF PATIENT-REPORTED OUTCOMES, 2025, 9 (01)